Enovis Corporation (ENOV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company has raised revenue, EBITDA, and EPS guidance, indicating strong financial performance. Despite a non-cash impairment, cash flow remains positive, with plans to reduce debt. Product launches and operational improvements are expected to drive growth. The Q&A reveals stable market conditions and positive sentiment towards future growth, despite management's reluctance to provide specific 2026 guidance. Given the market cap, this combination of factors suggests a positive stock price reaction in the short term.
Key Financial Performance
Third quarter revenue $549 million, up 9% year-over-year on a reported basis, including a 190 basis point benefit from foreign currency and 7% organic growth.
Recon business revenue Grew 9% organically, led by double-digit growth in Extremities and 7% in Hips and Knees globally. Growth attributed to product innovation and strategic synergies.
Prevention & Recovery (P&R) revenue Grew 4% organically, reflecting continued stability and mix benefits across the portfolio.
Free cash flow Nearly $30 million generated in the third quarter.
Adjusted gross margins Improved 140 basis points year-over-year, driven by favorable mix, ongoing productivity in manufacturing and supply chain, and slightly offset by tariff impacts.
Adjusted EBITDA margin 17.3%, down 60 basis points year-over-year, reflecting planned R&D investments, phasing of expenses, and tariffs.
Adjusted earnings per share (EPS) $0.75, up 3% year-over-year, driven by margin expansion and reduced interest expenses.
Year-to-date adjusted EPS Up 27%, driven by margin expansion and reduced interest expenses.
Interest expense $9 million for the quarter, down from $11 million last year.
Third quarter effective tax rate 21.8%.
Non-cash technical impairment of goodwill $548 million due to a sustained decline in share price and market capitalization. No impact on liquidity, cash flows, debt covenants, or future operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Augmented Reverse Glenoid (ARG) System: Continues to gain traction, early in the launch cycle with additional products in the pipeline for sustained innovation in extremities.
Nebula Stem and Orthodrive Impactor: Newly launched products performing well with excellent surgeon feedback.
Next-generation Arvis Ultra: Showcased in August, received outstanding surgeon response, lighter, faster, with advanced capabilities for knees and shoulders. Broader launch expected in the first half of 2026.
International Growth: Achieved 12% growth internationally, driven by Lima integration and cross-selling synergies across anatomies.
U.S. Recon Growth: Grew 7%, led by double-digit growth in extremities.
Adjusted Gross Margins: Increased by 140 basis points due to favorable mix and productivity improvements in manufacturing and supply chain.
Divestiture of Dr. Comfort: Completed sale for up to $60 million, sharpening focus on core markets and higher-margin opportunities.
Focus on Core P&R Markets: Aligned strategy to concentrate on higher growth and higher-margin opportunities by divesting Dr. Comfort.
Capital Allocation: Prioritized debt reduction and lower leverage levels with proceeds from divestiture and positive cash flow.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impacts: Tariffs have negatively impacted adjusted EBITDA margins, with $4 million paid in Q3, mostly related to the Prevention & Recovery (P&R) segment. The company is feeling the effects of these costs as they work through inventory, and the tariff situation remains fluid, posing ongoing risks to profitability.
Goodwill Impairment: A non-cash technical impairment of goodwill amounting to $548 million was recorded due to a sustained decline in share price and market capitalization. While it does not impact liquidity or operations directly, it reflects market challenges and could affect investor confidence.
Divestiture of Dr. Comfort: The sale of the diabetic foot care business, Dr. Comfort, will reduce revenue by $15 million in Q4. While the divestiture aligns with strategic goals, it creates short-term revenue and margin pressures.
R&D Investments and Expense Phasing: Planned R&D investments and expense phasing have contributed to a 60 basis point decline in adjusted EBITDA margin year-over-year, indicating challenges in balancing innovation with profitability.
Foreign Currency Volatility: A 190 basis point benefit from foreign currency was noted, but such benefits are subject to volatility and could pose risks to financial performance if exchange rates shift unfavorably.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has updated its full-year 2025 revenue guidance to $2.24 billion to $2.27 billion, reflecting a $5 million adjustment due to the divestiture of Dr. Comfort. Organic growth guidance remains unchanged.
Adjusted EBITDA Guidance: The company has raised its adjusted EBITDA guidance to a range of $395 million to $405 million, a $3 million increase, inclusive of favorable tariff outlooks, solid Q3 results, and the divestiture impact.
Adjusted EPS Guidance: The adjusted EPS guidance has been raised by $0.05 to a range of $3.10 to $3.25.
Cash Flow and Debt Reduction: The company expects positive cash flow for the year, which will be prioritized towards debt reduction and achieving lower leverage levels by the end of 2025.
Product Launch - Arvis Ultra: The next-generation Arvis Ultra is on track for a broader launch in the first half of 2026, featuring enhancements like soft tissue balancing for knees and advanced shoulder applications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing a slowdown in the U.S. revision market for Hips and Knees?
A:Q4 procedure volume seems healthy and stable. Historically, markets have been resilient despite factors like entitlement cuts, government policy changes, and inflationary concerns.
Q:How are you thinking about potential headwinds and tailwinds in 2026, and is high single-digit recall growth still on the table for next year?
A:Management is not guiding on 2026 yet but sees potential for high single-digit recall growth.
Q:What is your perspective on portfolio management and transformation?
A:The focus is on commercial execution, operational excellence, and financial discipline. Portfolio management includes SKU rationalization and cash generation, with everything being on the table.
Q:How should we expect the pace of the Arvis Ultra full launch following its full launch next year?
A:The launch is planned for Q1 and Q2 of 2026, with a broader expansion. The company is offering flexible financial models for customers to purchase, lease, or commit to implants.
Q:What are the drivers of upside to your current guide and positioning for 2026?
A:Drivers include commercial execution, account acquisition, account penetration, innovation prioritization, customer targeting, and operational improvements like gross margin focus and inventory rationalization.
Q:How are you thinking about setting up free cash flow for 2026?
A:The focus is on debt paydown and reducing leverage levels. Integration costs and European medical device regulation costs are expected to decrease significantly in 2026, aiding free cash flow momentum.
Q:Has the delay in Arvis impacted implant sales, and will Arvis drive growth in U.S. Hip and Knees?
A:The delay has not impacted implant sales. Arvis is expected to drive growth in U.S. Hip and Knees as part of an interconnected ecosystem.
Q:What are the Q4 guidance assumptions, and why are margins flat?
A:Q4 has a 4%+ headwind due to fewer days. Tariffs have a 50 basis point impact on EBITDA margins, and there is a modest impact from divestitures.
Q:How did foot and ankle volumes trend in the third quarter?
A:There was a rebound in foot and ankle volumes, supported by innovation and customer engagement.
Q:What are your thoughts on the J&J DePuy spin-off?
A:Management declined to comment on the spin-off but looks forward to competing with whoever owns it.
Q:What is the impact of the Dr. Comfort divestiture on margins and growth?
A:The divestiture provides a slight tailwind to growth and margins, as the business had lower margins and flat-to-declining growth.
Q:Why was U.S. Hip and Knee down 1%, and what is the outlook for implants?
A:The decline was due to a pause in Arvis sales. Implants in the U.S. grew mid-single digits, and Arvis is expected to drive future growth.
Q:What is driving strength in Recon internationally?
A:Growth is driven by cross-selling, product launches like Prima and SMR shoulder, and improved in-country execution.
Q:What is the impact of new product launches like Nebula and Orthodrive on growth?
A:New product launches are expected to contribute to above-market growth in Recon, with high single-digit growth anticipated.
Q:How do you view the contribution of price versus volume for new product launches?
A:New product launches are expected to mitigate market headwinds in price and support account acquisition.
Q:What is the split between Hips and Knees growth?
A:Both Hips and Knees are growing at similar rates, with new product launches expected to accelerate growth.
Q:Can you pass through pricing benefits in P&R to offset tariffs?
A:Pricing increases have been introduced cautiously to offset tariff impacts, but market dynamics are being considered.
Q:What is driving strength in extremities, particularly shoulders?
A:Strength is driven by ARG, which aids in customer conversion and deeper account penetration. Pricing remains stable, with some pressure from ASC mix.
Q:What is your long-term target for free cash flow conversion, and when will it be achieved?
A:The target is 70%-80% free cash flow conversion against adjusted net income, with progress expected in 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026, particularly on high single-digit recall growth and free cash flow conversion targets. They also declined to comment on the J&J DePuy spin-off.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARG traction
ASC month
ASC setting
Arvis ASC
Arvis Ultra
BoneStim cycle
Carrie conference
Dr PR
Dr Promus
Hips Knees
Prevention Recovery
Promus Equity
Recon digit
Relations today
benefit
capital
care
cash flow
date
divestiture Dr
extremity
flow debt
hospital
impairment
implant
manufacturing supply
outlook
strength
supply chain
surgeon
tariff
transaction
ENOV Transcript
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with significant revenue growth, improved gross margin, increased operating and net income, and a 25% rise in EPS. The absence of negative insights or concerns in the Q&A section further supports a positive outlook. Given the market cap of $2.46 billion, the robust financial metrics are likely to lead to a strong positive stock price reaction over the next two weeks.
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript
Positive2-27
The company reported strong financial performance with a 10% YoY revenue growth, improved gross margins, and increased net income. Despite the lack of specific shareholder return plans, the positive guidance adjustments for revenue, EBITDA, and EPS indicate optimism. The absence of concerning Q&A responses further supports a positive outlook. Given the market cap of approximately $2.46 billion, the stock is likely to experience a positive reaction, falling in the 2% to 8% range over the next two weeks.
Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Enovis Corporation (ENOV) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
ENOV Slides
ENOV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
